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KEYWORDS: Prion infection, scrapie, transmissible spongiform encephalopathy, TSE, interspecies 36 transmission, dog, canids, canine, PMCA, transgenic mouse models, transmission barrier, prion 37 susceptibility BSE, sheep scrapie, atypical sheep scrapie, atypical BSE-L, sheep-BSE and chronic wasting disease, among 48 others) none of which could infect them. The brains of these mice were subjected to in vitro prion 49 amplification and failed to find even minimal amounts of misfolded prions providing definitive 50 experimental evidence that dogs are resistant to prion disease. Subsequently, a second transgenic model 51 was generated in which aspartic acid in position 163 was substituted for asparagine (the most common 52 amino acid in this position in prion susceptible species) and this mutation resulted in susceptibility to BSE-53 derived isolates.
54
These findings strongly support the hypothesis that the amino acid residue at position 163 of canine PrP C 55 is a major determinant of the exceptional resistance of the canidae family to prion infection and establish 56 this as a promising therapeutic target for prion diseases. 57 58 AUTHOR SUMMARY 59 Cats, cattle, people and dogs were all exposed to mad cow disease but, unlike the other three, dogs never 60 succumbed to the disease. We generated a mouse model expressing canine prion protein (instead of 61 mouse prion protein) to provide experimental evidence that dogs are resistant to prion infection by 62 challenging the mice with a panel of prion isolates. None of the prions could infect our transgenic mice 63 that expressed dog prion protein. When the prion protein amino acid sequence of dogs was compared to 64 that of other susceptible species, one amino acid in a specific position was found to be different to all the 65 prion-susceptible animals. To determine if this amino acid was the one responsible for dogs' resistance to 66 prions, a second mouse model was generated with the canine prion protein but the critical amino acid 67 was substituted for the one susceptible species have. When this model was challenged with the same 68 panel of prions it could be infected with at least one of them. These results demonstrate the relevance of 69 this amino acid position in determining susceptibility or resistance to prions, and this information can be 70 used to design preventative treatments for prion diseases.
INTRODUCTION

73
Prion diseases are a group of invariably fatal neurodegenerative disorders for which no effective 74 treatment or prophylaxis exist currently. Many mammalian species are susceptible and all share a 75 common pathogenesis: the misfolding of the host-encoded cellular prion protein (PrP C ) into a pathological 76 conformer (PrP res ) that accumulates in the brain leading to neurodegeneration and death [1] [2] [3] . Research 77 efforts have been directed primarily at human prionopathies and those of domestic animals of commercial 78 interest. However, other species have been of interest either as a disease model or due to their lack of 79 susceptibility to infection. The study of species with significantly different prion susceptibilities is key to 80 understanding the biological mechanisms underlying these diseases.
82
The PrP C misfolding event can be sporadic (putatively spontaneous), caused by mutations in the PRNP 83 gene or triggered by externally acquired infectious prions. Currently, the "mad cow disease" epizootic is 84 under control but other animal prion diseases, such as scrapie in small ruminants or chronic wasting 85 disease (CWD) in cervids, are endemic in many countries and the recent spread of CWD to the European 86 continent is of great concern[4,5]. 
144
In the present study, a transgenic mouse line has been generated bearing wild type E163 dog PRNP and 145 challenged with a variety of prion isolates. To prove that the presence of a negatively charged amino acid 146 at position 163 in canine PrP C is critical in determining resistance to prion disease, one additional 147 transgenic mouse line was generated expressing dog PRNP but with asparagine 163 (D163N) as this 148 residue at this position is present in most of the prion susceptible species. This model was then exposed 149 to the same panel of isolates.
150
In this study, we confirm for the first time that dog PrP C is unable to propagate any of the prion isolates 179
None of the isolates tested was able to misfold TgDog E163 PrP C (Supplementary information, Fig. S2 ).
181
TgDog E163 bioassay: Even though in vitro results usually correlate well with bioassay, ultimately, 182 infectivity can only be demonstrated by in vivo inoculation. The isolates used for inoculation were the 183 ones described in the in vitro section above and negative control inocula were also included consisting of 184 normal brain homogenates (NBH) from cattle, dog and sheep.
185
None of the animals showed neurological clinical signs compatible with a TSE. [40] . In this 242 case the sheep-BSE inoculated mice brain pool served as a positive control.
243
With the exception of sheep-BSE inoculated mice, no PrP res propagated in any of the remaining brain pools 244 ( Fig. 2A and Supplementary information, Fig. S6 ). Serial PMCA was then repeated individually with the 245 brains of mice inoculated with sheep-BSE in which no PrP res had been detected by WB or IHC. Of these 246 animals, 10 out of 11 had PrP res present after in vitro amplification confirming the effectiveness of the 247 PMCA procedure to reveal subclinical prion infections on 1 st passage bioassay (Fig. 2B) . Homogenates from 248 the mouse brains inoculated with cattle BSE were also tested individually by serial PMCA and all of them 249 failed to propagate PrP res (Fig. 2B) Fig. S3 ) confirming the results obtained in the bioassay.
282
The total absence of prion infection or in vitro propagation with any of the prions used to challenge TgDog 283 could be attributed to reasons other than the extreme resistance of canine PrP C to misfolding such as 284 inherent issues with the generation of the transgenic models that may prevent infection. However, this 285 was ruled out through a thorough Western blot analysis of the PrP C of these transgenic animals that showed a virtually identical migration and glycosylation pattern to wild type dog PrP C (albeit expressed at 287 twice the levels) indicating correct posttranslational modifications (Supplementary information, Fig. S1 ).
288
Additionally, the immunohistochemical localization indicated the correct anatomical expression of the 289 protein on the neuronal cell membrane (Supplementary information, Fig. S1B ). Furthermore, the same 290 transgenic generation methodology for obtaining models for other prion disorders has been proven 291 successful previously [28, 43] . Altogether, the results support the conclusion that dog PrP C amino acid 292 residue sequence is solely responsible for the complete resistance to prion infection observed in this 293 transgenic model.
295
The only report unequivocally demonstrating that dog PrP C can be misfolded was achieved only in vitro, 
